Abstract
Fan et al. demonstrate that ovarian cancer reprograms the epigenome of stromal cells, inducing a mesenchymal-to-epithelial transition (MET) to form carcinoma-associated mesenchymal stem cells (CA-MSCs). This MET, mediated by WT1 and EZH2, enables CA-MSC:cancer cell co-metastasis. EZH2 inhibition decreases CA-MSC-mediated metastasis, presenting a potential therapeutic opportunity in ovarian cancer.
| Original language | English |
|---|---|
| Article number | 108473 |
| Journal | Cell Reports |
| Volume | 33 |
| Issue number | 10 |
| DOIs | |
| State | Published - 08 12 2020 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2020 The Author(s)
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- EZH2
- WT1
- carcinoma-associated mesenchymal stem cells
- epigenomic reprogramming
- mesenchymal-to-epithelial transition
- metastasis
- ovarian cancer
- tumor microenvironment
Fingerprint
Dive into the research topics of 'Epigenomic Reprogramming toward Mesenchymal-Epithelial Transition in Ovarian-Cancer-Associated Mesenchymal Stem Cells Drives Metastasis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver